Systemic IFN-I Synergizes with Topical TLR7/8 Agonists to Suppress Metastatic Tumors
Advancing targeted cancer immunotherapy is pivotal for overcoming distant metastasis and tumor relapse. The recent study in Nature Cancer by Sanlorenzo et al. demonstrates a breakthrough strategy combining systemic type I interferon with topical Toll-like receptor 7/8 agonists, where oral imiquimod...
Saved in:
| Main Authors: | Haiting Xu, Chenghui Wang, Bo Xiao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2025-01-01
|
| Series: | Research |
| Online Access: | https://spj.science.org/doi/10.34133/research.0739 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer
by: Ping Jin, et al.
Published: (2025-04-01) -
A Novel Application Paradigm for Tumor In-Situ Vaccination: Synergistic Effects of TLR7/8 Agonists and Radiotherapy
by: Xiaolin YOU, et al.
Published: (2025-07-01) -
The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine
by: Michael W. Crawford, et al.
Published: (2025-07-01) -
TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity
by: Shuting Wu, et al.
Published: (2025-01-01) -
All-Natural Gelatin-Based Nanoemulsion Loaded with TLR 7/8 Agonist for Efficient Modulation of Macrophage Polarization for Immunotherapy
by: Ritabrita Goswami, et al.
Published: (2024-09-01)